Filing Flows › Comparisons › STOK vs PYXS
Stoke Therapeutics vs Pyxis Oncology: STOK and PYXS compared
Stoke Therapeutics is the larger company: $11.3M of revenue in its latest quarter (Q3 2026) against $11.0M for Pyxis Oncology (Q4 2025). Pyxis Oncology is more profitable, with an operating margin of -165.7% against -686.9%.
Where the money goes: STOK and PYXS
Stoke Therapeutics (STOK) · Q3 2026
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
Pyxis Oncology (PYXS) · Q4 2025
Pyxis Oncology, Q4 2025: revenue $11.0M, operating margin -165.7%, net loss $18.1M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Stoke Therapeutics (STOK) | Pyxis Oncology (PYXS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 2025 |
| Revenue | $11.3M | $11.0M |
| Revenue growth, Y/Y | +6% | — |
| Operating margin | -686.9% | -165.7% |
| Net earnings | −$73.6M | −$18.1M |
| Net margin | -654.3% | -164.0% |
| Operating cash flow | −$62.7M | −$10.4M |
Questions
Which is bigger, Stoke Therapeutics or Pyxis Oncology?
Stoke Therapeutics is the larger company: $11.3M of revenue in its latest quarter (Q3 2026) against $11.0M for Pyxis Oncology (Q4 2025).
Is Stoke Therapeutics or Pyxis Oncology growing faster?
Pyxis Oncology is more profitable, with an operating margin of -165.7% against -686.9%.
More: Stoke Therapeutics earnings · how Stoke Therapeutics makes money · Pyxis Oncology earnings · how Pyxis Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-K filed Mar 23, 2026). Fiscal quarters can end on different dates. Not investment advice.